Asset Transaction, Private Placement (Form 8-K)

Item 2.01 Completion of Acquisition or Disposition of Assets.

As reported on the Current Report on Form 8-K of Advanced Biomed Inc. (the "Company") filed with the SEC on April 3, 2026, the Company entered into a Share Purchase Agreement (the "Share Purchase Agreement") on April 2, 2026, with Acellent Technologies (Hong Kong) Co. Limited (the "Target") and Mr. Xiaomin Chen, as the sole shareholder of the Target. Pursuant to the Share Purchase Agreement, the Company agreed to acquire 100% of the equity interest in the Target in exchange for the issuance of 270,000 shares of the Company's common stock, par value $0.001 per share, valued at $4.00 per share, for an aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026.

Item 3.02 Unregistered Sales of Equity Securities.

The information under Item 2.01 of this Current Report on Form 8-K related to the issuance of 270,000 shares of the Company's common stock to Mr. Xiaomin Chen is incorporated herein by reference.